BAUSCH HEALTH COS INC (BHC) Stock Fundamental Analysis
USA - NYSE:BHC - CA0717341071 - Common Stock
6.015 USD
-0.17 (-2.67%)
We assign a fundamental rating of 4 out of 10 to BHC. BHC was compared to 192 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of BHC while its profitability can be described as average. BHC is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
BHC had positive earnings in the past year.
BHC had a positive operating cash flow in the past year.
In the past 5 years BHC always reported negative net income.
BHC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BHC's Return On Assets of 1.35% is amongst the best of the industry. BHC outperforms 81.77% of its industry peers.
BHC has a Return On Invested Capital of 7.44%. This is amongst the best in the industry. BHC outperforms 84.90% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BHC is significantly below the industry average of 13.48%.
The 3 year average ROIC (5.98%) for BHC is below the current ROIC(7.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | N/A | ||
| ROIC | 7.44% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.98%
ROIC(5y)5.41%
1.3 Margins
The Profit Margin of BHC (3.61%) is better than 82.29% of its industry peers.
BHC has a Operating Margin of 20.68%. This is amongst the best in the industry. BHC outperforms 86.98% of its industry peers.
In the last couple of years the Operating Margin of BHC has grown nicely.
BHC has a better Gross Margin (70.67%) than 77.08% of its industry peers.
In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.68% | ||
| PM (TTM) | 3.61% | ||
| GM | 70.67% |
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BHC is still creating some value.
Compared to 1 year ago, BHC has more shares outstanding
BHC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BHC has an improved debt to assets ratio.
2.2 Solvency
BHC has an Altman-Z score of 0.25. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
BHC's Altman-Z score of 0.25 is in line compared to the rest of the industry. BHC outperforms 51.04% of its industry peers.
The Debt to FCF ratio of BHC is 19.41, which is on the high side as it means it would take BHC, 19.41 years of fcf income to pay off all of its debts.
BHC's Debt to FCF ratio of 19.41 is fine compared to the rest of the industry. BHC outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.41 | ||
| Altman-Z | 0.25 |
ROIC/WACC1.09
WACC6.82%
2.3 Liquidity
BHC has a Current Ratio of 1.30. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.30, BHC is not doing good in the industry: 76.04% of the companies in the same industry are doing better.
A Quick Ratio of 0.97 indicates that BHC may have some problems paying its short term obligations.
BHC has a Quick ratio of 0.97. This is in the lower half of the industry: BHC underperforms 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 1.33% over the past year.
Measured over the past years, BHC shows a decrease in Earnings Per Share. The EPS has been decreasing by -2.91% on average per year.
BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 5.86%.
BHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.28% yearly.
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
Revenue 1Y (TTM)5.86%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
3.2 Future
Based on estimates for the next years, BHC will show a decrease in Earnings Per Share. The EPS will decrease by -3.58% on average per year.
The Revenue is expected to decrease by -0.40% on average over the next years.
EPS Next Y5.69%
EPS Next 2Y6.32%
EPS Next 3Y-1.71%
EPS Next 5Y-3.58%
Revenue Next Year6.13%
Revenue Next 2Y5.11%
Revenue Next 3Y3.03%
Revenue Next 5Y-0.4%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 1.57 indicates a rather cheap valuation of BHC.
98.96% of the companies in the same industry are more expensive than BHC, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BHC to the average of the S&P500 Index (25.46), we can say BHC is valued rather cheaply.
With a Price/Forward Earnings ratio of 1.41, the valuation of BHC can be described as very cheap.
100.00% of the companies in the same industry are more expensive than BHC, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.39, BHC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.57 | ||
| Fwd PE | 1.41 |
4.2 Price Multiples
BHC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BHC is cheaper than 93.23% of the companies in the same industry.
BHC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.05 | ||
| EV/EBITDA | 6.67 |
4.3 Compensation for Growth
BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BHC has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y6.32%
EPS Next 3Y-1.71%
5. Dividend
5.1 Amount
BHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BHC (11/19/2025, 2:58:18 PM)
6.015
-0.17 (-2.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.96%
Inst Owner Change-8.02%
Ins Owners10.81%
Ins Owner Change0.51%
Market Cap2.22B
Revenue(TTM)10.03B
Net Income(TTM)362.00M
Analysts48.89
Price Target7.27 (20.86%)
Short Float %2%
Short Ratio3.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.24%
Min EPS beat(2)-7.07%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-8.49%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)4
Avg EPS beat(8)-3.92%
EPS beat(12)7
Avg EPS beat(12)-2.32%
EPS beat(16)8
Avg EPS beat(16)-5.93%
Revenue beat(2)2
Avg Revenue beat(2)0.5%
Min Revenue beat(2)0.36%
Max Revenue beat(2)0.64%
Revenue beat(4)3
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)0.64%
Revenue beat(8)6
Avg Revenue beat(8)0.85%
Revenue beat(12)9
Avg Revenue beat(12)1.1%
Revenue beat(16)9
Avg Revenue beat(16)-0.08%
PT rev (1m)-0.57%
PT rev (3m)-2.71%
EPS NQ rev (1m)1.16%
EPS NQ rev (3m)-2.98%
EPS NY rev (1m)0.64%
EPS NY rev (3m)-12.22%
Revenue NQ rev (1m)-0.15%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.57 | ||
| Fwd PE | 1.41 | ||
| P/S | 0.22 | ||
| P/FCF | 2.05 | ||
| P/OCF | 1.48 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.67 |
EPS(TTM)3.82
EY63.51%
EPS(NY)4.26
Fwd EY70.85%
FCF(TTM)2.93
FCFY48.73%
OCF(TTM)4.07
OCFY67.71%
SpS27.12
BVpS-1.53
TBVpS-45.11
PEG (NY)0.28
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | N/A | ||
| ROCE | 9.41% | ||
| ROIC | 7.44% | ||
| ROICexc | 7.91% | ||
| ROICexgc | 35.57% | ||
| OM | 20.68% | ||
| PM (TTM) | 3.61% | ||
| GM | 70.67% | ||
| FCFM | 10.81% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.98%
ROIC(5y)5.41%
ROICexc(3y)6.26%
ROICexc(5y)5.63%
ROICexgc(3y)44%
ROICexgc(5y)37.54%
ROCE(3y)7.57%
ROCE(5y)6.85%
ROICexgc growth 3Y34.27%
ROICexgc growth 5Y-5.74%
ROICexc growth 3Y14.02%
ROICexc growth 5Y12.75%
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.41 | ||
| Debt/EBITDA | 6.2 | ||
| Cap/Depr | 34.45% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 45.65% | ||
| Profit Quality | 299.45% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 0.25 |
F-Score7
WACC6.82%
ROIC/WACC1.09
Cap/Depr(3y)22.53%
Cap/Depr(5y)20.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
EPS Next Y5.69%
EPS Next 2Y6.32%
EPS Next 3Y-1.71%
EPS Next 5Y-3.58%
Revenue 1Y (TTM)5.86%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
Revenue Next Year6.13%
Revenue Next 2Y5.11%
Revenue Next 3Y3.03%
Revenue Next 5Y-0.4%
EBIT growth 1Y18.58%
EBIT growth 3Y5.56%
EBIT growth 5Y6.8%
EBIT Next Year12.61%
EBIT Next 3Y9.06%
EBIT Next 5Y-1.3%
FCF growth 1Y21.39%
FCF growth 3Y3.22%
FCF growth 5Y0.55%
OCF growth 1Y34.83%
OCF growth 3Y3.85%
OCF growth 5Y1.25%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
What is the valuation status for BHC stock?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 2 / 10.